摘要
抑制血管内皮生长因子A(VEGFA)/血管内皮生长因子受体2(VEGFR2)信号传导是肿瘤学中常见的治疗策略,抗血管生成药物作为一种重要的靶向药物已经广泛应用于肿瘤的临床治疗。随着新药物的不断发展,患者的生存率不断提高,其仍有许多不良反应,常见的为肾毒性,主要表现为蛋白尿。本文回顾VEGFA-VEGFR2抑制剂对肾毒性的实验验证机制及临床表现,同时介绍抗血管生成药物在临床使用过程中蛋白尿的发生率、相关机制及治疗方法,以阐明在保持治疗效果的同时最小化肾毒性的机制。
Inhibition of vascular endothelial growth factor A(VEGFA)/vascular endothelial growth factor receptor 2(VEGFR2) signaling is a common therapeutic strategy in oncology.As an important target drug,anti-angiogenic drugs have been widely used in the clinical treatment of tumor.With the development of new drugs,the survival rate of patients is increasing,but there are still many adverse reactions,and the common one is nephrotoxicity,mainly manifested as proteinuria.This article reviews the experimental mechanism and clinical manifestations of VEGFA-VEGFR2 inhibitor on renal toxicity,and introduces the incidence,related mechanism and treatment of proteinuria during the clinical use of antiangiogenic drugs,so as to clarify the mechanism of minimizing renal toxicity while maintaining the therapeutic effect.
作者
张超
陶莹
高文仓
ZHANG Chao;TAO Ying;GAO Wen-cang(The Second Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou 310000,China;Second Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310000,China)
出处
《实用药物与临床》
CAS
2020年第5期471-475,共5页
Practical Pharmacy and Clinical Remedies
基金
针灸微创肿瘤学课题(2017-XK-A12)。
关键词
抗血管生成靶向药物
肾脏损害
蛋白尿
机制
处理
Targeted antiangiogenic drugs
Kidney injury
Proteinuria
Mechanisms
Management
